The Latest

Pressure Mounts on Truvada PrEP Pricing With Lawsuit and Congressional Hearings

"This isn't about you," Rep. Alexandria Ocasio-Cortez (D-NY) told Gilead CEO Daniel O'Day. "We have legislated a system that allows [this] to happen."

By Tim Murphy

Will Recent Gilead Patent Concessions on Truvada Lower PrEP Prices?

Activists say this relatively small giveaway won't advance PrEP access or help end HIV in the U.S. the way a true price reduction would.

By Tim Murphy

If Nobody Slashes the Price of Truvada for PrEP, What Happens Next?

Activists and doctors say they're ready to go further if Gilead won't agree to -- or the U.S. government won't force -- a price reduction to make PrEP accessible to more Americans who need it.

By Tim Murphy

How Activists Uncovered CDC's Ownership of Truvada PrEP Patents

The #PrEP4All campaign made the call for affordable pre-exposure prophylaxis a national news story.

By Charles Sanchez

Sticker Shock: PrEP Is Not Cost-Effective at Current Price, Health Economists Find

But a survey reveals that about a third of black and Latino gay men would be willing to pay more than $50 per month for a prescription.

By Sony Salzman

PrEP Pricing Is the Elephant in the Room at the CDC National HIV Prevention Conference

In a debate during a plenary session, Michael Saag, M.D., argued for more activism to make PrEP accessible to people who need it.

By Sony Salzman

PrEP Pricing Problems

"A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified -- cost shouldn't be one of them," write James Krellenstein and Jeremiah Johnson.

By James Krellenstein and Jeremiah Johnson for Treatment Action Group

HIV Prevention: A Changing Outlook

Introduction AIDS Vaccines

The Thai Trial: A Shot in the Arm Other Vaccines Why Has AIDS Vaccine Research Been so Challenging? What's Next?

PrEP

Can a Pill a Day Prevent HIV?

Microbicides

Hope in 2010 Rectal Microbicides

Conclusion ...

By Deirdre Grant and Sarah Littlefield, M.P.H. for ACRIA and GMHC